CANADA: Sproutly Canada, announced an expansion of its operations with a new manufacturing facility in close proximity to the Toronto Herbal Remedies Inc production facility in Scarborough, Ontario. The additional property allows the Company to continue to centralize operations in the Greater Toronto Area, as well as providing manufacturing capabilities for it’s proprietary reagents, a key input for the APP Technology cannabinoid recovery process.
As Sproutly continues to explore other global markets for expansion, the need to produce its proprietary reagents at one central location and under EU GMP guidelines will be critical to ensuring consistency and quality, while at the same time reducing manufacturing costs. The new facility will also ensure that all space at THR is allocated to cannabis production and finished goods manufacturing.
The additional facility will not need to be licensed by Health Canada as no cannabis, or cannabis products, will be present on site.
Keith Dolo, Chief Executive Officer, Sproutly Canada commented, “This expansion, is being designed and constructed to be compliant with European Union GMP specifications, which will enable Sproutly to manufacture proprietary reagents for use not only in Canada, but also for distribution into other global markets.”